Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods

Overview

The Therapeutic Goods Act 1989 was enacted to provide for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, to protect the health and safety of the public. This legislation was introduced to address issues related to the quality, safety, and efficacy of therapeutic goods entering the Australian market. The Therapeutic Goods Administration, a part of the Department of Health, is the body responsible for administering and enforcing this Act. One of the primary policy objectives of the Act is to ensure that therapeutic goods available to consumers are of acceptable quality and do not pose a risk to public health. In the context of Cyclopet Pty Ltd, the Therapeutic Goods Administration has suspended their licence to manufacture therapeutic goods at the request of the manufacturer, effective from 19 August 2020 to 19 August 2021. This action underscores the commitment to maintaining stringent standards and the regulatory oversight required to uphold public health and safety in the distribution and manufacture of therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989 applies to a range of entities involved in the manufacture, supply, advertising, and evaluation of therapeutic goods within Australia. The Act governs entities such as manufacturers, importers, and suppliers of therapeutic goods, ensuring that these products are safe, of high quality, and effective for their intended use. The Therapeutic Goods Administration (TGA), as part of the Department of Health, is responsible for administering the Act, which includes the power to grant, suspend, or cancel licences for the manufacture of therapeutic goods. The Act's jurisdiction extends across the Commonwealth of Australia, affecting entities and individuals involved in the therapeutic goods supply chain nationwide. Exclusions or exemptions from the Act are generally limited and subject to specific conditions or categories of goods, such as certain types of complementary medicines or research-grade products, which may be regulated under different legislative frameworks. The Act can also be extended or restricted through subordinate instruments, such as regulations and guidelines, which provide further detail on the implementation and enforcement of the primary Act. The publication of the suspension of a manufacturer’s licence, as seen in the case of Cyclopet Pty Ltd, demonstrates the TGA's active role in maintaining the integrity and safety of the therapeutic goods market in Australia.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) provides a legal framework for regulating therapeutic goods in Australia, including the suspension of manufacturing licences under section 41(1)(d) (s.41(1)(d)). This particular Gazette notice concerns the suspension of a Licence to Manufacture Therapeutic Goods held by Cyclopet Pty Ltd, Licence number MI-2010-LI-03381-3, based at Basement Level 2, Macquarie University Hospital, 3 Technology Place, Macquarie University, NSW. The suspension was initiated by the Secretary of the Department of Health and was made at the request of the manufacturer, Cyclopet Pty Ltd, and it is effective from 19 August 2020 to 19 August 2021. This suspension halts the company's ability to manufacture therapeutic goods during this period. The Act imposes several obligations on parties holding a manufacturing licence, including compliance with good manufacturing practices, ensuring that therapeutic goods are safe and of high quality, and maintaining proper records. The suspension of Cyclopet Pty Ltd’s licence means they are temporarily barred from manufacturing any therapeutic goods, which likely includes stringent checks and balances to ensure that the suspension is adhered to and that no manufacturing activities occur during this period. They must also comply with any additional conditions stipulated by the Therapeutic Goods Administration (TGA) as part of the suspension. Failure to comply with the provisions of the Act, including the conditions of a licence suspension, can result in significant consequences. Section 11 of the Act outlines various offences and penalties for breaches, which can include both civil and criminal penalties. For example, knowingly manufacturing a therapeutic good while a licence is suspended can result in fines and/or imprisonment. The maximum penalties for such offences can include fines of up to $2,200,000 for corporations and imprisonment for up to 10 years. Additionally, the TGA can seek court orders to seize and destroy non-compliant goods, further enforcing the regulatory framework established by the Act.